Abstract:Background Stroke is one of the most common neurological diseases in the world and is clinically manifested by transient or permanent brain dysfunction. It has a high mortality and disability rate, which severely affects people's health and diminishes the quality of life. However, there is no efficient treatment that can be considered curative and there are other less well-known theories of pathogenesis. Therefore, it is imperative to gain a full understanding of the pathophysiology of ischemia and to seek new therapeutic strategies. Methods We first examined Kir4.1 channel and myelin based protein (MBP) expression in brain tissues from acute ischemic patients by Western blotting. We then established a transient ischemic mouse model (tMCAO) to conduct molecular, cell biological, transmission electron microscopy and pharmacokinetic studies, as well as in Kir4.1 cKO mice. Finally, neuroimaging and behavioral analyses were used to examine whether activation of Kir4.1 channel by luteolin could contribute to neuronal functional recovery in ischemic stroke. Findings In acute ischemic stroke patients, we first demonstrated that Kir4.1 ion channels were greatly impaired and a severe demyelination of axons occurred in ischemic infarction area of cerebral cortex in these patients. Further ev-idence showed that the deficits of Kir4.1 channels in NG2 glia led to the myelin loss of axons in a transient ischemic mouse model (tMCAO). Treating ischemic mice with a natural botanical extract, luteolin augmented Kir4.1 channel currents in NG2 glia and consequently promoted remyelination of axons, alleviated the infarction area and ultimately improved motor function in a series of behavioral tests. Interpretation Targeting Kir4.1 ion channels expressed in NG2 glial cells by luteolin treatment highlights an effective therapeutic strategy for a prompt brain functional recovery in ischemic stroke. Copyright (c) 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Glutamate-releasing BEST1 channel is a new target for neuroprotection against ischemic stroke with wide time window

Network-Based Approach to Identify Potential Targets and Drugs That Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke

Excitatory Synaptic Transmission in Ischemic Stroke: A New Outlet for Classical Neuroprotective Strategies

Disrupted Ionic Homeostasis in Ischemic Stroke and New Therapeutic Targets.

ULK1 confers neuroprotection by regulating microglial/macrophages activation after ischemic stroke

Glutamate acts on acid-sensing ion channels to worsen ischaemic brain injury

Glutamate as a co-agonist for acid-sensing ion channels to aggravate ischemic brain damage

Signaling Pathways in Brain Ischemia: Mechanisms and Therapeutic Implications.

BK Channel-Mediated Microglial Phagocytosis Alleviates Neurological Deficit after Ischemic Stroke

Phosphoproteomic Analysis Identifies Potassium Voltage-Gated Channel KCNQ2 and Anxa6 Alleviates Syt1-Mediated Ischemic Neuron Injury

Glutamate Antagonists in Therapy of Stroke

Excitotoxic Storms of Ischemic Stroke: A Non-neuronal Perspective

Sustained blood glutamate scavenging enhances protection in ischemic stroke

Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage

Kir4.1 Channel Activation in NG2 Glia Contributes to Remyelination in Ischemic Stroke

Therapeutic Neuroprotective Effects of XQ-1H in a Rat Model of Permanent Focal Cerebral Ischemia

Optogenetic Activation of Astrocytes Reduces Blood-Brain Barrier Disruption Via IL-10 in Stroke.

Phosphoproteome Analysis Identifies a Synaptotagmin-1-Associated Complex Involved in Ischemic Neuron Injury

Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor

Potential Neuroprotective Treatment of Stroke: Targeting Excitotoxicity, Oxidative Stress, and Inflammation